Biopharmaceutical company AstraZeneca issued notices last year to pharmacies regarding potential data discrepancies related to Farxiga dispensing and purchasing. The notices requested documentation supporting 2024 Farxiga dispensing and purchasing activity. Now that generic versions are available, there is heightened scrutiny as to whether pharmacies dispensed Farxiga or its generic equivalent, dapagliflozin, and whether purchasing aligns with billed claims.
Frier Levitt attorney Harini Bupathi discusses what these communications mean for pharmacies in her Dispense Times article, “AstraZeneca’s Recent Round of Letters to Pharmacies Expands Farxiga Dispensing and Billing Review — What Pharmacies Need to Know Now.” AstraZeneca’s communications reflect a broader trend of manufacturers independently reviewing pharmacy billing and purchasing compliance. Pharmacies that receive these communications should understand their response obligations and promptly consult experienced legal counsel. A timely, structured response is critical.
AstraZeneca’s Recent Round of Letters to Pharmacies Expands Farxiga Dispensing and Billing Review — What Pharmacies Need to Know Now
Access the full Dispense Times January-February 2026 Issue (article found on page 28): Dispense Times
